Medical Equipment

Oncology Biomarkers Market Developments Shaping Growth Across The Forecast Period

April 15, 2026April 15, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Oncology Biomarkers Market Expected To Change From 2026 To 2030?

The oncology biomarkers market has seen rapid expansion in recent years. Its value is set to increase from $17.3 billion in 2025 to $19.73 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.1%. The expansion observed in prior periods stemmed from the broader deployment of cancer screening programs, progress in molecular biology research, wider availability of biomarker testing platforms, an increase in oncology clinical trials, and growing partnerships between research bodies and hospitals.

The oncology biomarkers market is projected for substantial expansion over the upcoming years, reaching $33.63 billion by 2030, driven by a compound annual growth rate (CAGR) of 14.3%. This anticipated growth is largely due to factors such as the heightened demand for individualized oncology treatments, the advancement of AI-powered biomarker identification, greater financial commitments to cancer genomics research, the increasing implementation of liquid biopsy techniques, and an intensified emphasis on prompt cancer diagnosis and surveillance. Key developments expected during this timeframe encompass the wider acceptance of precision oncology diagnostics, a surge in the application of genetic and protein biomarkers, increased incorporation of bioinformatics for biomarker analysis, a broadening of companion diagnostics innovation, and a stronger commitment to tailored cancer treatment approaches.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/oncology-biomarkers-global-market-report

What Key Factors Are Shaping The Oncology Biomarkers Market Landscape?

The increasing occurrence of cancer is anticipated to fuel the expansion of the oncology biomarker market in the future. Cancer is characterized by certain body cells multiplying without control and gradually disseminating throughout the body. Oncological biomarkers offer enhanced insight into the specific cancer type by examining an individual’s genes, proteins, and other bodily substances. For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, by 2050, over 35 million new cancer cases were projected, representing a 77% increase compared to the estimated 20 million cases in 2022. Consequently, the growing prevalence of cancer is boosting the development of the oncology biomarkers market.

Which Segments Define The Oncology Biomarkers Market Segment Structure?

The oncology biomarkers market covered in this report is segmented –

1) By Biomarker Type: Protein Biomarkers, Genetic Biomarkers, Other Biomarker Types

2) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia, Ovarian Cancer, Liver Cancer, Other Cancer Types

3) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications

4) By End-User: Hospitals, Academic And Cancer Research Institutes, Diagnostic Laboratories

Subsegments:

1) By Protein Biomarkers: Tumor-Specific Antigens, Circulating Tumor Cells (CTCs), Enzymatic Biomarkers

2) By Genetic Biomarkers: DNA Mutations, Gene Expression Profiles, Single Nucleotide Polymorphisms (SNPs)

3) By Other Biomarker Types: Metabolomic Biomarkers, Epigenetic Biomarkers, MicroRNA Biomarkers

What Market Trends Are Affecting The Oncology Biomarkers Market?

Major companies operating in the oncology diagnostics market are concentrating on creating sophisticated biomarker-based assays to enhance early cancer identification, track minimal residual disease (MRD), and evaluate patient response to treatments. Minimal residual disease refers to the minute quantities of cancer cells that might persist in the body following therapy, potentially causing relapse if not identified. For instance, in May 2024, Tempus, a US-based artificial intelligence and precision medicine company, introduced its MRD test portfolio, including the xM test and the xM (NeXT Personal Dx) test developed by Personalis. The portfolio offers both tumor-naïve and tumor-informed assays, specifically designed to identify early cancer recurrence and residual disease, in addition to observing patient response to immunotherapy. These assays utilize circulating tumor biomarkers to furnish clinicians with precise and actionable insights, aiding in guiding patient management.

Who Are The Established Players Within The Oncology Biomarkers Market?

Major companies operating in the oncology biomarkers market are F Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Siemens Healthcare GmbH, Becton Dickinson and Company, GE Healthcare Technologies Inc., Eurofins Scientific SE, Agilent Technologies Inc., Hologic Inc., Illumina Inc., bioMerieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN NV, Exact Sciences Corporation, Sysmex Corporation, PerkinElmer Inc., Leica Biosystems, Myriad Genetics Inc., Guardant Health Inc., Enzo Biochem Inc., Biocartis Group NV, Agendia Inc., Epigenomics AG, OncoDNA SA

Get The Full Oncology Biomarkers Market Report:

https://www.thebusinessresearchcompany.com/report/oncology-biomarkers-global-market-report

Which Region Is The Top Contributor To The Oncology Biomarkers Market By Share?

North America was the largest region in the oncology biomarkers market in 2025. The regions covered in the oncology biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Oncology Biomarkers Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/oncology-biomarkers-global-market-report

Browse Through More Reports Similar to the Global Oncology Biomarkers Market 2026, By The Business Research Company

Cancer Biomarker Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Clinical Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report

Clinical Oncology Next Generation Sequencing Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-oncology-next-generation-sequencing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795